**Figure 3.** **TGF-β1 induces cellular senescence in VSMCs.** (**A**) TGF-β1 concentrations in serum from control donors and MFS patients was measured using an ELISA. n=6. (**B**) Western blotting and quantitative analysis of TGF-β1 levels in control- and MFS-VSMCs. n=3. (**C**) Western blotting and quantitative analysis of TGF-β1, p53 and p21 levels in control-VSMCs left untreated or treated with TGF-β1 or TGF-β1 combined with control-siRNA or TGF-β1-siRNA. n=3. (**D**) Representative images and quantitative analysis of SA-β-gal staining in control-VSMCs left untreated or treated with TGF-β1 or TGF-β1 combined with control-siRNA or TGF-β1-siRNA. n=3. Numbers of SA-β-gal-positive cells are expressed as percentages of the total cells. Data are expressed as the mean±SEM. **p<0.05, ***p<0.01, ***p<0.001.*